このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Denali Therapeutics 将来の成長

Future 基準チェック /26

Denali Therapeutics利益と収益がそれぞれ年間11.2%と26.4%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-35.5% 16.6%なると予測されています。

主要情報

11.2%

収益成長率

16.6%

EPS成長率

Biotechs 収益成長	24.1%
収益成長率	26.4%
将来の株主資本利益率	-35.5%
アナリストカバレッジ	Good
最終更新日	03 Jun 2024

今後の成長に関する最新情報

Recent updates

Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

May 23

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

May 13

An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Apr 17

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Mar 21

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Mar 07

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Feb 21

Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

Jan 26

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Nov 20

Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

Oct 09

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Aug 22

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price

May 02

Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be

Mar 04

Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation

Feb 06

These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat

Nov 09

Denali Therapeutics proposes $250M stock offering; shares down 6% post market

Oct 18

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Oct 12

Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122

Oct 10

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Jun 08

Denali Therapeutics Inc. (NASDAQ:DNLI) Analysts Just Slashed This Year's Estimates

Mar 07

Denali Therapeutics: 2021 Was Mostly Bad Luck And Trouble

Feb 25

Are Investors Undervaluing Denali Therapeutics Inc. (NASDAQ:DNLI) By 28%?

Feb 14

業績と収益の成長予測

NasdaqGS:DNLI - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	264	-395	-238	-214	10
12/31/2025	107	-464	-399	-289	15
12/31/2024	46	-426	-502	-258	16
3/31/2024	295	-137	-425	-413	N/A
12/31/2023	331	-145	-371	-358	N/A
9/30/2023	341	-124	-348	-332	N/A
6/30/2023	343	-128	-321	-302	N/A
3/31/2023	101	-371	-248	-231	N/A
12/31/2022	108	-326	-263	-245	N/A
9/30/2022	111	-303	-254	-238	N/A
6/30/2022	112	-284	-234	-222	N/A
3/31/2022	83	-286	-243	-233	N/A
12/31/2021	49	-291	-220	-211	N/A
9/30/2021	353	30	361	368	N/A
6/30/2021	357	56	404	410	N/A
3/31/2021	340	58	415	420	N/A
12/31/2020	336	71	413	416	N/A
9/30/2020	24	-228	-150	-145	N/A
6/30/2020	28	-216	-183	-176	N/A
3/31/2020	26	-215	-193	-176	N/A
12/31/2019	27	-198	-169	-152	N/A
9/30/2019	148	-66	-27	-11	N/A
6/30/2019	135	-55	-30	-15	N/A
3/31/2019	133	-52	-19	-14	N/A
12/31/2018	129	-36	47	50	N/A
9/30/2018	3	-137	-64	-61	N/A
6/30/2018	2	-123	-51	-49	N/A
3/31/2018	1	-91	-27	-24	N/A
12/31/2017	N/A	-88	N/A	-77	N/A
9/30/2017	N/A	-85	N/A	-77	N/A
6/30/2017	N/A	-93	N/A	-76	N/A
3/31/2017	N/A	-90	N/A	-75	N/A
12/31/2016	N/A	-87	N/A	-72	N/A

アナリストによる今後の成長予測

収入対貯蓄率: DNLI今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: DNLI今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: DNLI今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: DNLIの収益 ( 26.4% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: DNLIの収益 ( 26.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: DNLI 3 年以内に赤字になると予測されています。

Denali Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates fall by 29%

Consensus revenue estimates decrease by 49%

Price target decreased by 7.1% to US$48.53

Consensus EPS estimates upgraded to US$1.01 loss, revenue downgraded

Consensus revenue estimates increase by 279%

Consensus revenue estimates increase by 21%, EPS downgraded

Recent updates

Now 21% undervalued

Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

Consensus revenue estimates fall by 29%

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023)

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating Eif2b Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial

Denali Therapeutics Inc., Annual General Meeting, May 31, 2024

An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Director notifies of intention to sell stock

New minor risk - Shareholder dilution

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Consensus revenue estimates decrease by 49%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Co-Founder notifies of intention to sell stock

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier-Crossing Enzyme Replacement Therapy Programs At Worldsymposium

Denali Therapeutics Inc. Announces Presentations on Its Investigational Blood-Brain Barrier (Bbb)-Crossing Enzyme Replacement Therapies At the Upcoming 2024 Worldsymposium

Insufficient new directors

Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

Co-Founder recently sold US$340k worth of stock

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Co-Founder notifies of intention to sell stock

Price target decreased by 7.1% to US$48.53

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Consensus EPS estimates upgraded to US$1.01 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

Denali Therapeutics Inc. Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Consensus revenue estimates increase by 279%

Co-Founder notifies of intention to sell stock

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Consensus revenue estimates increase by 21%, EPS downgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price

Consensus revenue estimates increase by 29%

Co-Founder notifies of intention to sell stock

Co-Founder exercised options and sold US$198k worth of stock

Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Consensus EPS estimates fall by 18%

Co-Founder recently sold US$105k worth of stock

Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle Development Programs for MPS Diseases at the Upcoming WORLDSymposium™

Co-Founder notifies of intention to sell stock

Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation

Co-Founder notifies of intention to sell stock

Co-Founder recently sold US$144k worth of stock

Co-Founder notifies of intention to sell stock

Denali Therapeutics Announces DNL343 Interim Phase 1B Data in ALS and Entry into the Healey ALS Platform Trial

Consensus forecasts updated

Consensus revenue estimates fall by 14%

These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat

Co-Founder notifies of intention to sell stock

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates increase by 10%

Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with Tak-594/Dnl593 (Ptv:Pgrn) and Progression to Enrolling Participants with Ftd-Grn

Denali Therapeutics proposes $250M stock offering; shares down 6% post market

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122

Biogen Inc. and Denali Therapeutics Announce Initiation of the Phase 3 Lighthouse Study in Parkinson's Disease Associated with Lrrk2 Pathogenic Mutations

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome)